Mavenclad
Mavenclad is an originator product from Merck (Schweiz) AG and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 1'970.30 to CHF 11'367.40 depending on the pack; the patient co-payment is 10 per cent plus the deductible.
Core data
- Authorisation holder
- Merck (Schweiz) AG
- ATC code
- L04AA40
- IT group
- 01.99 Varia
- Active substances
- Cladribinum
- Preparation type
- Originator product
- On the SL since
- 01/06/2019
- Last price change
- 01/09/2026
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Tabl 10 mg | Blist 1 Stk | CHF 1'796.56 | CHF 1'970.30 | 01/01/2023 | A | 7680668310012 |
| Tabl 10 mg | Blist 4 Stk | CHF 7'182.32 | CHF 7'676.85 | 01/01/2023 | A | 7680668310029 |
| Tabl 10 mg | Blist 6 Stk | CHF 10'779.36 | CHF 11'367.40 | 01/01/2023 | A | 7680668310036 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
Aktive schubförmige remittierende Multipler Sklerose (aktive RRMS)
Mavenclad wird vergütet für die Behandlung von erwachsenen Patienten mit aktiver schubförmig remittierender Multipler Sklerose (MS), definiert durch klinische oder bildgebende Befunde. Behandlung durch einen Facharzt der Neurologie.
Hochaktive schubförmige remittierende Multipler Sklerose (hochaktive RRMS)
Mavenclad wird vergütet zur Behandlung von erwachsenen Patienten mit hochaktiver schubförmig remittierender Multipler Sklerose (MS) definiert durch klinische oder bildgebende Befunde.
-
- Bei Patienten mit hoher Krankheitsaktivität trotz Behandlung mit einer krankheitsmodifizierenden Therapie (in der Regel während mindestens 6 Monaten), oder
- Bei therapienaiven Patienten richtet sich die Vergütung nach aktuell geltenden klinischen Leitlinien wie der DGN.
Behandlung durch einen Facharzt der Neurologie mit zeitlichem Zugang zu MRI.
FAQ
Is Mavenclad covered by Swiss health insurance?
Yes, but only under conditions. Mavenclad is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Mavenclad cost in Switzerland?
The public price is the maximum price set by the FOPH and for Mavenclad ranges from CHF 1'970.30 to CHF 11'367.40 per pack. The ex-factory price ranges from CHF 1'796.56 to CHF 10'779.36. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages